Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells $2,716,000.00 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 40,000 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $67.90, for a total value of $2,716,000.00. Following the completion of the transaction, the chief executive officer directly owned 575,686 shares in the company, valued at approximately $39,089,079.40. This represents a 6.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neil Kumar also recently made the following trade(s):

• On Thursday, April 9th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $74.62, for a total value of $2,984,800.00.
• On Thursday, March 12th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $68.73, for a total value of $2,749,200.00.
• On Thursday, February 19th, Neil Kumar sold 28,053 shares of BridgeBio Pharma stock. The shares were sold at an average price of $71.39, for a total value of $2,002,703.67.
• On Tuesday, February 10th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $71.94, for a total value of $2,877,600.00.

BridgeBio Pharma Stock Up 4.0%

Shares of BridgeBio Pharma stock opened at $68.61 on Thursday. The firm has a market cap of $13.44 billion, a price-to-earnings ratio of -18.34 and a beta of 1.02. The business has a 50-day moving average price of $71.28 and a 200-day moving average price of $71.66. BridgeBio Pharma, Inc. has a twelve month low of $31.77 and a twelve month high of $84.94.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.14). The firm had revenue of $194.52 million during the quarter, compared to analysts’ expectations of $178.07 million. The firm’s quarterly revenue was up 66.8% on a year-over-year basis. During the same period last year, the firm posted ($0.88) EPS. On average, equities analysts expect that BridgeBio Pharma, Inc. will post -2.28 EPS for the current fiscal year.

Key Stories Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Evercore ISI raised its price target on BridgeBio Pharma to $130 from $125 and kept an Outperform rating, signaling stronger confidence in the company’s outlook after the latest quarterly results. Article: Evercore ISI Retains an “Outperform Rating” on BridgeBio Pharma, Inc. (BBIO)
• Positive Sentiment: HC Wainwright raised earnings estimates across multiple periods, including FY2026, FY2027, and several quarterly forecasts, while reiterating a Buy rating and $110 price target; higher profit expectations often support valuation sentiment. Article: HC Wainwright estimate revisions on BridgeBio Pharma
• Positive Sentiment: BridgeBio also presented at the Bank of America Global Healthcare Conference, helping keep investor attention on its pipeline and commercial progress. Article: BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Analysts broadly remain constructive on BBIO, with recent coverage updates and a generally favorable “Moderate Buy” consensus reinforcing a positive but not surprise-driven backdrop. Article: Analysts Offer Insights on Healthcare Companies: Vericel (VCEL) and BridgeBio Pharma (BBIO)
• Negative Sentiment: CEO Neil Kumar sold 40,000 shares in a pre-arranged 10b5-1 transaction, which can weigh on investor sentiment even though the sale was planned. Article: SEC Form 4 insider sale by Neil Kumar
• Negative Sentiment: The company’s latest quarterly report missed EPS expectations, which is still a drag on sentiment despite stronger revenue growth and upbeat longer-term analyst revisions. Article: BridgeBio Pharma first-quarter 2026 results

Institutional Trading of BridgeBio Pharma

Several institutional investors and hedge funds have recently modified their holdings of BBIO. Aster Capital Management DIFC Ltd bought a new stake in shares of BridgeBio Pharma during the third quarter valued at approximately $31,000. Harvest Fund Management Co. Ltd bought a new stake in shares of BridgeBio Pharma during the third quarter valued at approximately $34,000. Jones Financial Companies Lllp bought a new stake in shares of BridgeBio Pharma during the first quarter valued at approximately $35,000. First Horizon Corp bought a new stake in shares of BridgeBio Pharma during the third quarter valued at approximately $36,000. Finally, Huntington National Bank raised its stake in shares of BridgeBio Pharma by 111.7% during the third quarter. Huntington National Bank now owns 743 shares of the company’s stock valued at $39,000 after acquiring an additional 392 shares in the last quarter. Institutional investors own 99.85% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. HC Wainwright increased their price target on shares of BridgeBio Pharma from $100.00 to $110.00 and gave the company a “buy” rating in a report on Monday. JPMorgan Chase & Co. increased their price target on shares of BridgeBio Pharma from $89.00 to $94.00 and gave the company an “overweight” rating in a report on Tuesday, March 10th. Barclays reaffirmed an “overweight” rating on shares of BridgeBio Pharma in a report on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BridgeBio Pharma in a report on Wednesday, January 21st. Finally, Mizuho reaffirmed an “outperform” rating and issued a $106.00 price target on shares of BridgeBio Pharma in a report on Tuesday, April 28th. Twenty-four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, BridgeBio Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.19.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.